

**Literaturverzeichnis zum Beitrag Seltene Erkrankungen – „Kawasaki-Syndrom“
von Professor Dr. Johannes-Peter Haas und Dr. Toni Hospach
Bayerisches Ärzteblatt 10/2020, Seite 488 ff.**

1. Kawasaki, T., [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. *Arerugi*, 1967. 16(3): p. 178-222.
2. Newburger, J.W., et al., Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics*, 2004. 114(6): p. 1708-33.
3. Nakamura, Y., et al., Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. *J Epidemiol*, 2010. 20(4): p. 302-7.
4. Makino, N., et al., Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. *Pediatr Int*, 2019. 61(4): p. 397-403.
5. Feldstein, L.R., et al., Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med*, 2020. 383(4): p. 334-346.
6. Tirelli, F., et al., One year in review: Kawasaki disease. *Curr Opin Rheumatol*, 2020. 32(1): p. 15-20.
7. Xie, X., X. Shi, and M. Liu, The Roles of Genetic Factors in Kawasaki Disease: A Systematic Review and Meta-analysis of Genetic Association Studies. *Pediatr Cardiol*, 2018. 39(2): p. 207-225.
8. Dietz, S.M., et al., Regression and Complications of z-score-Based Giant Aneurysms in a Dutch Cohort of Kawasaki Disease Patients. *Pediatr Cardiol*, 2017. 38(4): p. 833-839.
9. Cimaz, R. and R. Sundel, Atypical and incomplete Kawasaki disease. *Best Pract Res Clin Rheumatol*, 2009. 23(5): p. 689-97.
10. Benseler, S.M., et al., Infections and Kawasaki disease: implications for coronary artery outcome. *Pediatrics*, 2005. 116(6): p. e760-6.
11. Kobayashi, T., et al., Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. *J Pediatr*, 2013. 163(2): p. 521-6.
12. Kobayashi, T., et al., Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. *Lancet*, 2012. 379(9826): p. 1613-20.
13. Jakob, A., et al., Failure to Predict High-risk Kawasaki Disease Patients in a Population-based Study Cohort in Germany. *Pediatr Infect Dis J*, 2018. 37(9): p. 850-855.
14. Fabi, M., et al., Inability of Asian risk scoring systems to predict intravenous immunoglobulin resistance and coronary lesions in Kawasaki disease in an Italian cohort. *Eur J Pediatr*, 2019. 178(3): p. 315-322.
15. Rigante, D., et al., Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome. *Int J Mol Sci*, 2016. 17(3): p. 278.
16. Wang, W., et al., Macrophage activation syndrome in Kawasaki disease: more common than we thought? *Semin Arthritis Rheum*, 2015. 44(4): p. 405-10.

17. Taddio, A., et al., Describing Kawasaki shock syndrome: results from a retrospective study and literature review. *Clin Rheumatol*, 2017. 36(1): p. 223-228.
18. Salgado, A.P., et al., High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease. *J Pediatr*, 2017. 185: p. 112-116 e1.
19. McCrindle, B.W., et al., Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*, 2017. 135(17): p. e927-e999.
20. Eleftheriou, D., et al., Management of Kawasaki disease. *Arch Dis Child*, 2014. 99(1): p. 74-83.
21. Downie, M.L., et al., Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment. *Int J Cardiol*, 2017. 236: p. 157-161.
22. Sonoda, K., et al., Infliximab plus plasma exchange rescue therapy in Kawasaki disease. *J Pediatr*, 2014. 164(5): p. 1128-1132 e1.
23. Son, M.B., et al., Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. *Pediatrics*, 2009. 124(1): p. 1-8.
24. Son, M.B., et al., Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. *J Pediatr*, 2011. 158(4): p. 644-649 e1.
25. Shirley, D.A. and I. Stephens, Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin. *Pediatr Infect Dis J*, 2010. 29(10): p. 978-9.
26. Burns, J.C., et al., Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. *J Pediatr*, 2008. 153(6): p. 833-8.
27. Suzuki, H., et al., Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. *Pediatr Infect Dis J*, 2011. 30(10): p. 871-6.
28. McCrindle, B.W. and E.S. Selamet Tierney, Acute Treatment for Kawasaki Disease: Challenges for Current and Future Therapies. *J Pediatr*, 2017. 184: p. 7-10.
29. Wallace, C.A., et al., Initial intravenous gammaglobulin treatment failure in Kawasaki disease. *Pediatrics*, 2000. 105(6): p. E78.
30. Uehara, R., et al., Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. *Pediatr Infect Dis J*, 2008. 27(2): p. 155-60.
31. Durongpisitkul, K., et al., Immunoglobulin failure and retreatment in Kawasaki disease. *Pediatr Cardiol*, 2003. 24(2): p. 145-8.
32. Burns, J.C., et al., Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. *Pediatr Infect Dis J*, 1998. 17(12): p. 1144-8.
33. Hashino, K., et al., Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. *Pediatr Int*, 2001. 43(3): p. 211-7.

34. Shafferman, A., J.D. Birmingham, and R.Q. Cron, High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. *Pediatr Rheumatol Online J*, 2014. 12: p. 26.
35. Kone-Paut, I., et al., The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series. *Autoimmun Rev*, 2018. 17(8): p. 768-774.
36. Tremoulet, A.H., et al., Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). *Contemp Clin Trials*, 2016. 48: p. 70-5.
37. Fukazawa, R., Long-term prognosis of Kawasaki disease: increased cardiovascular risk? *Curr Opin Pediatr*, 2010. 22(5): p. 587-92.
38. Suda, K., et al., Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms: a single-institution experience. *Circulation*, 2011. 123(17): p. 1836-42.
39. Kitamura, S., et al., Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawasaki disease. *Circulation*, 2009. 120(1): p. 60-8.
40. Chang, R.K., Hospitalizations for Kawasaki disease among children in the United States, 1988-1997. *Pediatrics*, 2002. 109(6): p. e87.
41. Viner, R.M. and E. Whittaker, Kawasaki-like disease: emerging complication during the COVID-19 pandemic. *Lancet*, 2020. 395(10239): p. 1741-1743.
42. Cherif, M.Y., et al., Coronavirus disease 2019-related Kawasaki-like disease in an adult: A case report. *JAAD Case Rep*, 2020. 6(8): p. 780-782.